|Last Price$93.22||Day Change (%)-0.97%|
|Open Price$94.50||Day Change ($)-0.91|
|Day Range93.05–94.51||52-Week Range72.77–95.50|
As of Thu 10/02/2014 06:20 AM EST | USD
Research and Markets: Uveitis Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
Research and Markets: Global Antibiotics Market 2014-2018: AstraZeneca, Eli Lilly, GSK, Johnson & Johnson, Novartis , Pfizer & Sanofi Lead the Market
The company's diverse operating divisions and robust pipeline should lead to steady growth.
ADC Therapeutics Expands Team
CAHG Executive Vice President, Chief Creative Officer Robin Shapiro Promoted to President
UPDATE: These 10 boring stocks will beat your portfolio
Germany's Merck to Buy Sigma-Aldrich for $17 Billion--3rd Update
Top managers continue to focus on higher-quality dividend-paying stocks in a fully valued market.
Novartis NVS announced Friday that it is removing Zelnorm for irritable bowel syndrome from the U.S. market at the request of the Food and Drug Administration. We think Zelnorm could eventually return to pharmacy shelves in the United States, but we have drastically reduced our estimate of sales ...
Research and Markets: Global Cirrhosis Therapeutics Pipeline Review 2014 - 7 Companies & 8 Drug Profiles